UPDATE: Goldman Sachs Lowers PT to $22 on Impax Laboratories on Competitive Risks
Goldman Sachs reiterated its Sell rating on Impax Laboratories (NASDAQ: IPXL) and reduced its price target from $24 to $22.
Goldman Sachs commented, "Third quarter revenues and disappointing fourth quarter guidance both suggest that competitive pressures in the generics segment are greater than we had anticipated. Weak Adderall XR sales as well as the further declines implied by guidance suggest that Actavis competition has driven greater-than-anticipated pricing pressure. Fourth quarter guidance was further pressured by earlier-than-expected fenofibrate competition."
Impax Laboratories closed at $24.34 on Friday.
Latest Ratings for IPXL
|Nov 2016||Bank of America||Downgrades||Neutral||Underperform|
|Sep 2016||Goldman Sachs||Upgrades||Sell||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.